Clinical trials: House Dust Mite Rhinitis
Allergic Rhinoconjunctivitis, Allergic Rhinitis
A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65
A research study of house dust mite (HDM) SLIT-tablet for the treatment of HDM allergy in Chinese participants aged 12-65.
- Trial name
- NCT07060885
- Testing
- HDM SLIT-tablet (12 SQ-HDM)
- Where
- 30 sites in China
- Volunteers
- 327 people
- Sponsor
- ALK-Abelló A/S
Asthma, House Dust Mite Allergy
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts
The purpose of this study is to investigate the safety of different doses of sublingual tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma.
- Trial name
- NCT01608243
- Testing
- SLIT tablets of house dust mite allergen extracts
- Where
- France
- Volunteers
- 94 people
- Sponsor
- Stallergenes Greer
Mite Allergy, Dermatophagoides Farinae Allergy
Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte
House dust mites are the main source of allergies in indoor environments. They are predominant in coastal areas, with the Canary Islands being the autonomous community with the highest percentage of patients with…
- Conditions
- Mite Allergy, Dermatophagoides Farinae Allergy, Dermatophagoides Pteronyssinus Allergy, Rhinitis, Allergic
- Trial name
- NCT07427576
- Testing
- Clustoid® Max Forte
- Where
- 2 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Inmunotek S.L.
Rhinitis, Allergic
Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites
Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites
- Conditions
- Rhinitis, Allergic, Perennial
- Trial name
- NCT00521131
- Testing
- Levocetirizine dihydrochloride
- Volunteers
- 453 people
- Sponsor
- UCB Pharma
Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate…
- Conditions
- Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis, House Dust Mite Allergy, Pollen Allergy
- Trial name
- NCT04874714
- Testing
- MM09-MG01(30.000-30.000), MG01(30.000), MM09(30.000)
- Where
- 13 sites in Spain
- Volunteers
- 18 people
- Sponsor
- Inmunotek S.L.
Allergic Rhinitis
Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy
The objective of this clinical trial is to assess the safety and efficacy of sublingual application of allergen extracts for specific immunotherapy in patients suffering from perennial allergic rhinitis due to house dust mites.
- Trial name
- NCT01014325
- Testing
- Allergen extract
- Where
- Spain
- Volunteers
- 130 people
- Sponsor
- Roxall Medizin
Allergy Dermatophagoides Pteronyssinus, Allergic Rhinitis
Biological Standardization of Dermatophagoides Pteronyssinus Allergen Extract
The objective of this study is to determine the biologic activity of a Dermatophagoides pteronyssinus allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Conditions
- Allergy Dermatophagoides Pteronyssinus, Allergic Rhinitis, Allergic Asthma
- Trial name
- NCT01821716
- Testing
- Prick test Dermatophagoides pteronyssinus allergen extract
- Where
- 2 sites in Spain
- Volunteers
- 42 people
- Sponsor
- Laboratorios Leti, S.L.
Allergic Rhinitis Due to House Dust Mite, Allergic Conjunctivitis Due to Dermatophagoides Farinae
Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust Mites
The goal of this non-interventional study is to investigate the safety and tolerability of a new simplified up-dosing schedule for Novo-Helisen Depot.
- Conditions
- Allergic Rhinitis Due to House Dust Mite, Allergic Conjunctivitis Due to Dermatophagoides Farinae, Allergic Conjunctivitis Due to Dermatophagoides Pteronyssinus, Allergic Asthma Due to Dermatophagoides Farinae
- Trial name
- NOVUS-UP (NCT07096440)
- Volunteers
- 105 people
- Sponsor
- Allergopharma GmbH & Co. KG
Allergic Rhinitis
Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic Rhinitis
A single center, double-blind, randomized, dose-escalation study to assess the safety, tolerability and efficacy of 3 doses of AD17002 in comparison to placebo.
- Trial name
- NCT04088721
- Testing
- AD17002, Formulation Buffer
- Where
- Taiwan
- Volunteers
- 48 people
- Sponsor
- Advagene Biopharma Co. Ltd.
Allergy to House Dust Mite, Allergic Asthma
Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients
The study will be conducted as a randomized, double-blind, placebo-controlled, single-center study in adult patients with mild controlled allergic asthma and house dust mite allergy.
- Trial name
- Tregulaire (NCT04673591)
- Testing
- Tregalizumab
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- T-Balance Therapeutics GmbH
Allergic Rhinitis, Rhinoconjunctivitis
Safety Study of Depigoid Vaccine Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml), to Treat Allergic Rhinitis or Rhinoconjunctivitis With or Without Asthma
Safety study of Depigoid vaccine Dermatophagoides pteronyssinus or 50% Dermatophagoides pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml), to treat allergic rhinitis or rhinoconjunctivitis with or without asthma.
- Conditions
- Allergic Rhinitis, Rhinoconjunctivitis, Mild Persistent Asthma, Mild Intermittent Asthma
- Trial name
- NCT01591343
- Testing
- Depigoid® (500 DPP/ml)
- Where
- 10 sites in Spain
- Volunteers
- 8 people
- Sponsor
- Laboratorios Leti, S.L.
Perennial Allergic Rhinoconjunctivitis, House Dust Mite Allergy
A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
The purpose of the study is to test the efficacy of the combination treatment AllQbG10 in patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy in a double-blind placebo-controlled setting
- Trial name
- NCT00574223
- Testing
- CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- Cytos Biotechnology AG
Allergic Rhinitis, Allergic Asthma
Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract
Prospective, randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of polymerized and mannan conjugated allergen extract of Dermatophagoides for the treatment of allergic…
- Conditions
- Allergic Rhinitis, Allergic Asthma, Allergic Rhinoconjunctivitis, Allergy to House Dust Mite
- Trial name
- MM09-SLIM (NCT05641272)
- Testing
- 3,000 MM09, 9,000 MM09
- Where
- Argentina
- Volunteers
- 90 people
- Sponsor
- Inmunotek S.L.
Respiratory Hypersensitivity
Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma
The trial is performed to assess efficacy and safety of the Allergopharma house dust mite allergoid in bronchial asthma.
- Trial name
- NCT00263640
- Testing
- Acaroid
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Allergopharma GmbH & Co. KG
House Dust Mite Allergy
Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis
The trial is performed to assess efficacy and safety of Novo-Helisen Depot in allergic Rhinoconjunctivitis
- Trial name
- NCT00263549
- Testing
- House dust mite Novo Helisen Depot
- Where
- Germany
- Sponsor
- Allergopharma GmbH & Co. KG
Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal
A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)
The purpose of this study is to evaluate the dose-related effectiveness, the safety and the tolerability of MK-8237, compared to placebo, in the treatment of house dust mite (HDM)-induced allergic rhinitis/rhinoconjunctivitis in…
- Trial name
- NCT01644617
- Testing
- MK-8237 6 DU, MK-8237 12 DU
- Volunteers
- 124 people
- Sponsor
- ALK-Abelló A/S
Rhinitis, Allergic, Perennial, House Dust Mite Allergy
Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR
The objective of this study was to assess the efficacy and safety of 12 months of treatment with 300 IR of STG320 sublingual tablets compared with placebo in adults and adolescents with HDM-associated allergic rhinitis.
- Trial name
- NCT02443805
- Testing
- 300 IR
- Where
- 2 sites in United States, France
- Volunteers
- 1,607 people
- Sponsor
- Stallergenes Greer
Allergic Disorder of Respiratory System
Evaluation of the Clinical Efficacy of PURESSENTIEL Allergy Protection Nasal Spray (SNPA®) in House Dust Mite Allergic Rhinitis- ACARAY Study
Justification of the relevance of the research: Patients suffering from allergic rhinitis are looking for several therapeutic options to control their symptoms.
- Trial name
- ACARAY (NCT07196527)
- Testing
- Puressentiel Allergy Protection Nasal Spray, Saline spray (0.65%)
- Volunteers
- 20 people
- Sponsor
- Puressentiel
Allergic Rhinitis, Allergic Rhinoconjunctivitis
MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009)
The purpose of this study is to assess the effect on various biomarkers of treatment with MK-8237 in participants with allergic rhinitis or rhinoconjunctivitis.
- Trial name
- NCT01852825
- Testing
- MK-8237, NAC
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Rhinitis, Rhinoconjunctivitis
Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df
The goal of this clinical trial is to learn if MM09 works to treat patients allergic to house mites, displaying rhinitis/rhinoconjunctivitis with or without mild to moderate asthma. It will also learn about the safety of MM09.
- Trial name
- Oraltek-58 (NCT07348302)
- Testing
- Allergen Immunotherapy Extract
- Where
- 19 sites in Argentina, China and 2 more
- Volunteers
- 736 people
- Sponsor
- Inmunotek S.L.